LOXL2 and Hepatic fibrosis: Compared to LOXL2 inhibition, treatment with a monoclonal antibody targeting specifically LOX did not alter liver fibrosis scores13, suggesting LOXL2 to be the superior target of antifibrotic therapy in these organs.